incidence and epidemiology
Follicular lymphomas (FLs) are the second most frequent subtype of nodal lymphoid malignancies in Western Europe. The annual incidence of this disease has rapidly increased during recent decades and has risen from 2-3/100 000 during the 1950s to 5/100 000 recently [1] .
diagnosis and pathology/molecular biology
Diagnosis should be based on a surgical specimen/excisional lymph node biopsy. Core biopsies should only be carried out in patients without easily accessible lymph nodes (e.g. retroperitoneal bulk), keeping in mind the possible heterogeneity of FL grading can be difficult to appreciate on core biopsies and re-biopsy may be required if the material is not adequate. Fine needle aspirations are inappropriate for a reliable diagnosis.
The histological report should give the diagnosis according to the World Health Organization (WHO) classification. Grading of lymph node biopsies is carried out according to the number of blasts/high-power field (Table 1) . FL grade 3A (with sheets of blasts) is considered an aggressive lymphoma and treated as such [2] , whereas grade 1, 2 and 3A should be treated as indolent disease [3] . Review, especially of grade 3A or 3B, by an expert haematopathologist is advised if the infiltration pattern is atypical (diffuse areas, even with small cells).
staging and risk assessment
Since treatment largely depends on the stage of the disease, initial staging should be thorough, particularly in the small proportion of patients with early stages I and II (10%-15%) ( Table 2) . Initial work-up should include a computed tomography (CT) scan of the neck, thorax, abdomen and pelvis, and a bone marrow aspirate and biopsy (Table 3) . Positron emission tomography (PET)-CT improves the accuracy of staging for nodal and extranodal sites and thus should be recommended for routine staging in FL [IV, C] [4] . This is particularly important to confirm localised stage I/II before involved-field radiotherapy.
A complete blood count, routine blood chemistry including lactate dehydrogenase (LDH), β2 microglobulin and uric acid as well as screening tests for human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C are required. The staging is carried out according to the Ann Arbor classification system (Table 2) , with mention of bulky disease (>7 cm) when appropriate.
For prognostic purposes, a 'Follicular Lymphoma-specific International Prognostic Index' (FLIPI, Table 4 ) has been established [I, A] [6] . A revised FLIPI 2 (incorporating β2 microglobulin, diameter of largest lymph node, bone marrow involvement and haemoglobin level) has been suggested for patients requiring treatment which may be more informative on progression-free survival (PFS) [7] .
Extended gene-expression profiling of tumour biopsy suggests a more favourable clinical course in cases with infiltrating T cells, in comparison with cases with non-specific macrophage bystander cells [5] . Recently, a clinicogenetic risk score (m7-FLIPI) has been proposed based on mutation status of seven candidate genes (EZH2, ARID1A, MEF2B, EP300, FOXO1, CREBBP and CARD11) [8] ; however, none of the techniques are yet established in clinical routine practice. In addition, several recent immunohistochemistry studies have reported conflicting data; hence, biological parameters are still investigational for prognostic assessment and are not yet suitable for clinical decision-making [9] . If possible, additional biopsy material should be stored fresh frozen to allow for the possible future application of additional molecular analyses. treatment first line stage I-II. In the small proportion of patients with limited non-bulky stages I-II, radiotherapy (involved field, 24 Gy) is the preferred treatment with a potentially curative potential, whereas the 2 × 2 Gy schedule is inferior and is merely palliative [II, B] [10] . In selected cases, watchful waiting or rituximab monotherapy may be considered to avoid the side-effects of radiation (e.g. cervical: sicca syndrome, hypothyroidism; abdominal: mucositis, myeloablative suppression) [11, 12] .
In stage I-II patients with large tumour burden, adverse clinical or biological prognostic features or when local radiotherapy is not applicable (e.g. lung, liver), systemic therapy as indicated for advanced stages should be applied [IV, B] [12] .
stage III-IV induction: In the majority of patients with advanced stage III and IV disease, no curative therapy is yet established. Since the FACS, fluorescence-activated cell sorting; PCR, polymerase chain reaction; LDH, lactate dehydrogenase; FLIPI 2, Follicular Lymphoma International Prognostic Index 2; HIV, human immunodeficiency virus; CT, computed tomography; PET-CT, positron emission tomographycomputed tomography; ASCT, autologous stem cell transplantation. In three randomised trials before the rituximab era, an early initiation of therapy in asymptomatic patients did not result in any improvement of disease-specific survival or overall survival (OS) [13] . In a more recent study, early initiation of rituximab resulted in improved PFS (80% versus 48%, P <0.001), but no survival benefit has been determined so far [14] , and the benefit of rituximab maintenance in this setting appears doubtful [15] . Thus, the current therapeutic approach is based on clinical risk factors, symptoms and patient perspective (Figure 1) .
Four prospective first-line trials, two salvage trials and a systematic meta-analysis confirmed an improved overall response, PFS and OS if rituximab was added to chemotherapy (Table 6 ) [16] [17] [18] [19] [20] . If complete remission and long PFS is to be achieved, rituximab in combination with chemotherapy such as CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) or bendamustine should be used [I, B] [17, 21] . CVP (cyclophosphamide, vincristine and prednisone) is not as effective as these two regimens with respect to PFS but not OS [22] . Figure 1 . Therapeutic algorithm. R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone; R-CVP, rituximab, cyclophosphamide, vincristine and prednisolone. Marcus et al. [16] 159 53 months 81% 27 83% (4 years) R-CVP (P < 0.0001) (P < 0.0001) (P = 0.029) Hiddemann et al. [17] 223 58 months 96% NR 90% (2 years) R-CHOP (P < 0.001) (P = 0.0493) Herold et al. [18] 105 48 months 92% NR 87% (4 years) R-MCP (P = 0.0009) (P < 0.0001) (P = 0.0096) Bachy et al. [19] 175 99 months 81% 66 79% (8 years) R-CHVP-IFN (P = 0.035) (P = 0.0004) (P = 0.076) Rummel et al. [21] 139 34 months 93% NR 84% (4 years) BR Federico et al. [22] 34 months 95% (3 years) R-CVP 178 88% 46% (3 years) R-CHOP 178 93% 62% (3 years) R-FM 178 91% 59% (3 years) + R maintenance Vitolo et al. [23] 234 42 months 86% NR 89% (3 years) 4× R-FND + 4× R ± R maintenance P, significance levels in comparison with chemotherapy only. FL, follicular lymphoma; R-CVP, cyclophosphamide, vincristine and prednisolone; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone; R-MCP: mitoxantrone, chlorambucil, prednisone; R-CHVP-IFN, rituximab, cyclophosphamide, doxorubicin, etoposide, prednisone, interferon; BR, bendamustine-rituximab; R-FM, rituximab, fludarabine and mitoxantrone; R-FND, cyclophosphamide, vincristine and prednisolone; NR, not reached. 
consolidation/maintenance
Rituximab maintenance for 2 years improves PFS (59% versus 43% after 6 years, P < 0.0001) [I, B] [27] , whereas a shorter maintenance period results in inferior benefit [28] .
Radioimmunotherapy consolidation also prolongs PFS after chemotherapy, but its benefit seems to be inferior in comparison with rituximab maintenance for 2 years [II, B] [29, 30] .
Myeloablative consolidation followed by autologous stem cell transplantation (ASCT) prolongs PFS after chemotherapy, but its benefit after a rituximab-containing induction is minor and no OS has been observed [31] . Therefore, such an approach is not recommended in first-line therapy of responding patients [I, D].
relapsed disease
At relapse, it is strongly recommended to obtain a new biopsy in order to exclude transformation into an aggressive lymphoma. It may be useful to target the biopsy based on PET scanning.
As at first presentation, observation is an accepted approach in asymptomatic patients with low tumour burden.
Selection of salvage treatment depends on efficacy of prior regimens. In early relapses (<12-24 months), a non-cross-resistant scheme should be preferred (e.g. bendamustine after CHOP or vice versa). Other options, including fludarabine-based, platinum saltsbased or alkylating agents-based regimens, could also be useful. Rituximab should be added if the previous antibody-containing scheme achieved >6-to 12-month duration of remission [IV, B] . On the other hand, obinutuzumab has recently received a positive recommendation for approval by the European Medicines Agency for rituximab-refractory cases based on an improved PFS in comparison with bendamustine only [I, B] [32] .
In symptomatic cases with low tumour burden, rituximab monotherapy may be applied. Rituximab maintenance for up to 2 years has a favourable side-effect profile and, based on a systematic meta-analysis, substantially prolongs PFS and OS in relapsed disease, even after antibody-containing induction in patients who have not received antibody as first-line therapy [I, A] [33] . A second-line maintenance treatment has not been investigated in the setting of maintenance use in first line and probably should not be used for those patients who had relapsed during their first maintenance period [IV, D]. High-dose chemotherapy with ASCT prolongs PFS and OS and should be considered, especially in patients who experience short-lived first remissions (<2-3 years) after rituximab-containing regimens, which usually have a much worse long-term outcome, but its general role in the rituximab era has to be redefined [I, B] [34] [35] [36] [37] . A subsequent rituximab maintenance may achieve some improvement in PFS [II, B] [38] .
In later relapses, monotherapy is an established option with palliative intent [II, B] . The PI3K inhibitor idelalisib has been registered in double-refractory FL, based on a phase II study [39] . Recent analyses suggest an increased mortality risk as a consequence of pulmonary morbidity (atypical pneumonias/ pneumonitis), so appropriate prophylaxis (cotrimoxazole/ acyclovir) is strongly recommended. Cytomegalovirus monitoring may be also advised.
In selected younger patients with later relapses of high-risk profile or relapse after ASCT, a potentially curative allogeneic stem cell transplantation ( preferably with dose-reduced conditioning) may be considered, especially in patients with early relapse and refractory disease [IV, B] [36] .
innovative approaches
In recent years, new approaches, including lenalidomide-rituximab and additional inhibitors of the B-cell signalling pathway, have proved active in phase II studies, but to date their benefit response evaluation
Appropriate imaging evaluation should be carried out midterm and after completion of chemotherapy. Patients with an inadequate response [less than partial response (PR)] should be evaluated for early salvage regimens. PR patients may convert to complete response (CR) under rituximab maintenance. PET-CT after completion of chemotherapy induction has been recommended for prognostic reasons as persistent PETpositivity (using appropriate Deauville scales) identifies a small group (20%-25%) of patients with a worse prognosis [40] , but therapeutic consequences remain undefined [II, B] .
Minimal residual disease (MRD) analysis by polymerase chain reaction at the end of the treatment is an independent predictor of long-term outcome, but should not guide therapeutic strategies outside of clinical studies.
personalised medicine
As various therapeutic approaches may achieve durable responses in the vast majority of patients, the selection of optimal treatment is mainly based on clinical risk factors, symptoms and patient perspective (Figure 1) . PET-and MRD-based tailored treatments are currently evaluated in studies but are not yet routine clinical practice.
Paediatric FL is an FL variant originally described in children, but occurs in adults as well. It is characterised by a localised disease, the absence of bcl-2 aberrations, lack of t(14;18), grade III and a high proliferation rate. It shows a much more indolent course and should be managed with local therapy only, despite displaying histologically more aggressive features [41] .
follow-up and long-term implications and survivorship
The following minimal recommendations are based on consensus rather than on evidence (Table 7) :
• After local radiotherapy: history and physical examination every 6 months for 2 years, subsequently once a year if clinically indicated.
• After (during continuous) systemic treatment: history and physical examination every 3-4 months for 2 years, every 6 months for 3 additional years, and subsequently once a year [V, D].
• Blood count and routine chemistry every 6 months for 2 years, then only as needed for evaluation of suspicious symptoms.
• Evaluation of thyroid function in patients with irradiation of the neck at 1, 2 and 5 years.
• Minimal adequate radiological or ultrasound examinations every 6 months for 2 years and optionally annually up to 5 years. Regular CT scans are not mandatory outside of clinical trials, especially if abdominal ultrasound is applicable. PET-CT should be not used for surveillance.
• MRD screening may be carried out in clinical studies but should not guide therapeutic strategies.
methodology
These clinical practice guidelines were developed in accordance with the ESMO standard operating procedures for clinical practice guidelines development, http://www.esmo.org/Guidelines/ ESMO-Guidelines-Methodology. The relevant literature has been selected by the expert authors. A summary of recommended treatment strategies outside of clinical studies is provided in Figures 2 and 3 , and a summary of recommendations is provided in Table 8 . Levels of evidence and grades of recommendation have been applied using the system shown in Table 9 . Statements without grading were considered justified 
